Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing ...

NVO trades at a forward P/E of 14 and PFE at just 8x, making both the cheapest large-cap healthcare names despite strong ...

Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield ...

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic ...

Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share ...

Broad market bearishness prompts defensive buys in oversold defense stocks, high-yield Pfizer, and cash reserves. Read more ...

Novo Nordisk A/S outlook: 2026 guidance warns revenue/profit declines as GLP-1 competition, pricing pressure & patent risks ...

Over the weekend, I was talking with a family friend who was moving some money around. I asked what he planned to do with the cash left over. I was hoping his answer wasn’t put it in a low interest ...

In the latest close session, Pfizer (PFE) was down 2.75% at $24.04. The stock trailed the S&P 500, which registered a daily loss of 0.1%. On the other hand, the Dow registered a gain of 0.35%, and the ...